Citadel Advisors’s Cyclerion Therapeutics CYCN Stock Holding History

Citadel Advisors’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$28K	Buy	+18,261	New	+$26K	﹤0.01%	12592
2022 Q4	–	Sell	-533	Closed	-$6.3K	–	14932
2022 Q3	$9K	Buy	+533	New	+$9.16K	﹤0.01%	12293
2022 Q1	–	Sell	-4,657	Closed	-$112K	–	13733
2021 Q4	$160K	Buy	4,657 +988	+27%	+$46.7K	﹤0.01%	12181
2021 Q3	$225K	Sell	3,669 -846	-19%	-$55.4K	﹤0.01%	11726
2021 Q2	$352K	Buy	4,515 +3,804	+535%	+$238K	﹤0.01%	10875
2021 Q1	$40K	Buy	+711	New	+$53.4K	﹤0.01%	12978
2019 Q4	–	Sell	-11,720	Closed	-$2.84M	–	9205
2019 Q3	$2.84M	Sell	11,720 -3,202	-21%	-$692K	﹤0.01%	3941
2019 Q2	$3.42M	Buy	+14,922	New	+$4.22M	﹤0.01%	3654

Other funds holding CYCN

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Kovack Advisors Ft. Lauderdale, Florida $1.87B AUM 29.51% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

Citadel Advisors's CYCN Position: Q1 2026 in Review

Citadel Advisors opened a new position in Cyclerion Therapeutics (CYCN) in Q1 2026: 18,261 shares worth $28K. The stake represents ﹤0.01% of the portfolio and ranks #12592 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in CYCN as recently as Q3 2022.

Citadel Advisors first reported a position in CYCN in Q2 2019 and has held it in 8 quarters since. The position peaked at $3.42M in Q2 2019. 17 funds tracked by Wall St. Rank hold CYCN as of Q1 2026.

Citadel Advisors held 18,261 shares of Cyclerion Therapeutics worth $28K as of Q1 2026.
Cyclerion Therapeutics was a new Citadel Advisors position in Q1 2026.
Cyclerion Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12592 holding.
Citadel Advisors first reported a position in Cyclerion Therapeutics in Q2 2019 and has held it in 8 quarters since.
Citadel Advisors's Cyclerion Therapeutics position peaked at $3.42M in Q2 2019.
17 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.